Last updated: 11/07/2018 16:45:58
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg*, 100mcg*, 200mcg*, or 400mcg* for 14 days in Adult and Adolescent Subjects with SARs.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg*, 100mcg*, 200mcg*, or 400mcg* for 14 days in Adult and Adolescent Subjects with SARs.
Trial description: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg*, 100mcg*, 200mcg*, or 400mcg* for 14 days in Adult and Adolescent Subjects with SARs.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Martin BG, Ratner PH, Hampel FC, Andrews CP, Toler T, Wu W, Faris MA, Philpot EE. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007;28: 216-225.
Nathan RA, Martin BG, Ratner PH, Hampel FC, Andrews CP, Toler T, Wu W, Faris MA, Philpot EE. Fluticasone furoate nasal spray provides 24-hour relief of nasal and ocular symptoms of seasonal allergic rhinitis with once-daily dosing. Allergy Asthma Proc 2
Stanford R, Philpot E, Faris M, Toler T, Wu W. Fluticasone furoate nasal spray once-daily improves nocturnal quality of life in subjects with seasonal allergic rhinitis (SAR). Ann Allergy Asthma Immunol 2007;98(1) (Suppl 1): A88 (abstract life in subject
Stanford R, Philpot E, Faris M, Toler T, Wu W. Fluticasone furoate nasal spray once-daily improves quality of life in subjects with seasonal allergic rhinitis (SAR). Ann Allergy Asthma Immunol 2007;98(1) (Suppl 1): A90 (abstract). subjects with seasonal
Medical condition
Rhinitis, Allergic, Seasonal
Product
fluticasone furoate
Collaborators
Not applicable
Study date(s)
December 2003 to February 2004
Type
Not applicable
Phase
2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2004-05-02
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website